CLINICAL TRIAL OF MET'S MICROCAN SYRINGE SUCCESSFUL
Micromedic Technologies notified the Tel Aviv Stock Exchange that its subsidiary, Microvascular Eye Technology successfully completed clinical trials in France of its MicroCan, a device that directly delivers therapeutic agents to the retinal blood vessel. The trials restored vision of a person suffering from retinal vein occlusion. Two of the three patients in the trial were treated with the device alone, without medication. The third patient, injected with a drug through the MicroCan, had vision restored to a functional level after three weeks.